Celldex Therapeutics, Inc.
CLDXIn Vitro & In Vivo Diagnostic Substances · SIC 2835 · CIK 0000744218
Revenue FY2025
$2.0M
Net Income
$(259.0M)
EPS (Basic)
$-3.90
Net Margin
-16748.0%
ROE
-49.1%
Total Equity
$527.0M
Shares Out
79M
Celldex Therapeutics, Inc. — In Vitro & In Vivo Diagnostic Substances. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 3 funds in our universe
Insider Transactions
Reading stored insider transactions…